Avraham Frisch

Haifa, HA, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML.

Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML.

Journal: EJHaem
Published: March 19, 2026

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Journal: Annals of hematology
Published: January 29, 2026

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Journal: Annals of hematology
Published: January 29, 2026

Intensive induction therapy with FLAG-idarubicinvenetoclax for fit older high-risk patients with acute myeloid leukemia.

Intensive induction therapy with FLAG-idarubicinvenetoclax for fit older high-risk patients with acute myeloid leukemia.

Journal: Haematologica
Published: December 25, 2025

The sobering reality of fertility preservation in young female patients with acute leukemia.

The sobering reality of fertility preservation in young female patients with acute leukemia.

Journal: Haematologica
Published: September 02, 2025

FLAG-IDA-venetoclax for high-risk newly diagnosed acute myeloid leukemia: a multicenter real-world study.

FLAG-IDA-venetoclax for high-risk newly diagnosed acute myeloid leukemia: a multicenter real-world study.

Journal: Haematologica
Published: August 25, 2025

Novel therapies for acute myeloid leukemia. Does age still matter?

Novel therapies for acute myeloid leukemia. Does age still matter?

Journal: Blood reviews
Published: March 14, 2025

HiDAC Consolidation in AML: Comparable Outcomes With Reduced Toxicity Using a Three-Day Schedule (HiDAC-123).

HiDAC Consolidation in AML: Comparable Outcomes With Reduced Toxicity Using a Three-Day Schedule (HiDAC-123).

Journal: European journal of haematology
Published: March 11, 2025

Epiglottitis in Patients Treated for Acute Leukemia: Case Series and Systematic Review of the Literature.

Epiglottitis in Patients Treated for Acute Leukemia: Case Series and Systematic Review of the Literature.

Journal: Acta haematologica
Published: January 04, 2025

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

Journal: British journal of haematology
Published: September 30, 2024

Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

Journal: European journal of haematology
Published: August 29, 2024

Acute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing.

Acute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing.

Journal: Haematologica
Published: June 05, 2024
Showing 1-12 of 27

Last Updated: 09/26/2026